Oxidative stress contributes to muscle atrophy in chronic kidney disease patients

Objectives Patients with chronic kidney disease have impaired muscle metabolism, resulting in muscle atrophy. Oxidative stress has previously been identified as a significant contributor to muscle atrophy in other populations, but the contribution in chronic kidney disease is unknown. The aim of thi...

Full description

Saved in:
Bibliographic Details
Published in:Redox report : communications in free radical research 2015-05, Vol.20 (3), p.126-132
Main Authors: Beetham, Kassia S, Howden, Erin J, Small, David M, Briskey, David R, Rossi, Megan, Isbel, Nicole, Coombes, Jeff S
Format: Article
Language:English
Subjects:
Aged
Biomarkers - blood
Body Mass Index
Cross-Sectional Studies
F2-Isoprostanes - blood
Female
Humans
Kidney diseases
Linear Models
Male
Middle Aged
Muscle strength
Muscular atrophy
Muscular Atrophy - etiology
Muscular Atrophy - metabolism
Oxidative stress
Oxidative Stress - physiology
Protein Carbonylation
Renal Insufficiency, Chronic - complications
Renal Insufficiency, Chronic - metabolism
Renal Insufficiency, Chronic - physiopathology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objectives Patients with chronic kidney disease have impaired muscle metabolism, resulting in muscle atrophy. Oxidative stress has previously been identified as a significant contributor to muscle atrophy in other populations, but the contribution in chronic kidney disease is unknown. The aim of this study was to investigate the association between oxidative stress, grip strength, and lean mass in patients with chronic kidney disease. Methods This is a cross-sectional study of 152 participants with stage 3 or 4 chronic kidney disease. Outcome measures include grip strength, lean mass, plasma total F2-isoprostanes, inflammation, peak oxygen uptake, and standard clinical measures. Results Thirty four (22.4%) chronic kidney disease patients had elevated oxidative stress levels (plasma F2-isoprostanes >250 pg/ml), with 82% of patients below age-predicted grip strength normative values. There was a significant negative association between plasma F2-isoprostanes and grip strength (r = −0.251) and lean mass (r = −0.243). There were no associations with inflammation markers. Multiple linear regression identified plasma F2-isoprostanes as a significant predictor of grip strength independent of other predictors: sex, diabetes status, body mass index, body fat percent, and phosphate (adjusted r 2 = 69.5, P < 0.001). Discussion Plasma F2-isoprostanes were independently associated with reduced strength in chronic kidney disease patients.
ISSN:1351-0002
1743-2928
DOI:10.1179/1351000214Y.0000000114